About Arboretum Ventures
Arboretum Ventures is a venture capital firm founded in 2002. It is primarily based out of Ann Arbor, United States. As of Mar 2026, Arboretum Ventures is an active investor, having invested in 68 companies, with 1 new investment in the last 12 months. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to HealthTech and High Tech. Most recently it participated in the $***** Series C round of Endogenex Overall, Arboretum Ventures portfolio has seen 3 IPOs and 22 acquisitions including key companies like Aira, Inogen and Esperion Therapeutics. A lot of funds co-invest with Arboretum Ventures, with names like Versant Ventures sharing a substantial percentage of its portfolio. Arboretum Ventures has team of 14 people including 3 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 6 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
Arboretum Ventures' List of Top Investments
Arboretum Ventures has a portfolio of 68 companies. Their most notable investments are in ViaLase and Virtual Incision.Their portfolio spans across United States, Canada and Israel. They have invested in Life Sciences, HealthTech, High Tech and 4 other sectors, across stages such as Series A, Series B and 6 more. Here is the list of top investments by Arboretum Ventures:1. Aira
Provider of remote assistance solution for blinds and the visually impaired. It provides smart glasses app that enables users to connect with a network certified agents along with family and friends. The agents use a real-time interactive cloud-based dashboard built to provide an augmented reality context for remote users by the processing of live data streams from cameras, GPS, and other sensor systems from wearable platforms.
Key facts about Aira
- Founded Year: 2014
- Location: Carlsbad (United States)
- Stage: Acquired
- Total Funding till date: $192M
- Employee Count: 171 as on Sep 30, 2026
- Investors: Deep Learning, Felicis Ventures and 10 Others
- Latest Funding Round: Series B, Jan 16, 2024, $*****
- Highlight: Acquired
2. Koya Medical
Provider of smart wearable compression technology for lymphedema and venous diseases. The company offers its flagship product Dayspring system which is an FDA-cleared wearable device which offers an active compression system and pump. The device is integrated with an app that indicated the treatment of lymphedema, venous insufficiency, and wound healing time. The device uses patented Flexframe technology.
Key facts about Koya Medical
- Founded Year: 2018
- Location: Oakland (United States)
- Stage: Series B
- Total Funding till date: $37M
- Employee Count: 188 as on Aug 31, 2026
- Investors: Zühlke, Orbimed and 10 Others
- Latest Funding Round: Series B, Nov 15, 2023, $*****
- Highlight: Editors' Pick
Transforming cardiac rhythm management with innovative extravascular pacing and defibrillation solutions. This medical device company is dedicated to designing novel extravascular leads and deployment systems, aiming to eliminate the risks and drawbacks of traditional transvenous leads. They focus on both pacing and defibrillation solutions, offering a new option for pacing without entering the heart and life-saving ICD benefits without transvenous leads. Their extravascular solutions place leads outside the vasculature and heart, maintaining the integrity of the heart while delivering much-needed therapy. They are developing the EV Temporary Pacing Lead System and the EV-ICD Lead System, both designed to address pacing and defibrillation needs without entering the heart or vascular system. This innovative approach seeks to reduce complications associated with transvenous leads and improve patient outcomes in cardiac rhythm management. They are focused on medical devices, electrophysiology, cardiology, temporary pacing, extracardiac, and extravascular solutions.
Key facts about AtaCor Medical
- Founded Year: 2014
- Location: San Clemente (United States)
- Stage: Series D
- Total Funding till date: $137M
- Employee Count: 34 as on Sep 30, 2026
- Investors: aMoon, Broadview Ventures and 7 Others
- Latest Funding Round: Series D, Oct 06, 2025, $*****
- Highlight: Editors' Pick
4. Inogen
Provider of a portable oxygen concentrator for oxygen therapy. The device provides a 5-liter continuous flow of oxygen per minute. It removes nitrogen to deliver purified oxygen via nasal cannula.
Key facts about Inogen
- Founded Year: 2001
- Location: Goleta (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $51.6M
- Employee Count: 854 as on Sep 30, 2026
- Investors: Western Technology Investment, Versant Ventures and 6 Others
- Latest Funding Round: Series D, Apr 12, 2012, $*****
- Highlight: Public
Developer of lipoprotein cholesterol (LDL-C) lowering therapies. Its drug pipeline includes Bempedoic Acid (ETC-1002) (Inhibitor of ATP Citrate Lyase) which is low-density lipoprotein cholesterol (LDL-C) lowering small molecule designed to lower elevated levels of LDL-C and to avoid side effects associated with existing LDL-C lowering therapies; ESP41091 and ApoA-1 Mimetics.
Key facts about Esperion Therapeutics
- Founded Year: 1998
- Location: Ann Arbor (United States)
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $107M
- Employee Count: 354 as on Sep 30, 2026
- Investors: BB Biotech, Oberland Capital and 16 Others
- Latest Funding Round: Post IPO, Apr 26, 2021, $*****
- Highlight: Acquired
Arboretum Ventures' Year-on-Year Investment Trends
Arboretum Ventures has invested in 68 companies over the last 23 years, with an average of 3 new investments annually in the last 10 years. In 2025, it made 5 investments, while as of Mar 2026, it has made 1 investment in this year. Its most recent first time investment was in Endogenex and most recent follow-on round was in Boomerang Medical.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 1 | 0 | 1 |
2025 | 1 | 4 | 5 |
2024 | 7 | 3 | 10 |
2023 | 1 | 2 | 3 |
2022 | 3 | 3 | 6 |
2021 | 6 | 3 | 9 |
2020 | 3 | 2 | 5 |
2019 | 3 | 2 | 5 |
2018 | 3 | 3 | 6 |
2017 | 2 | 1 | 3 |
Arboretum Ventures' Investments by Stage
Arboretum Ventures has made 27 investments in Series A stage with an average round size of $19.2M, 13 investments in Series B stage with an average round size of $14M and 13 investments in Series C stage with an average round size of $30.1M.Stage of entry | No. of Investments |
|---|---|
Series A | 27 |
Series B | 13 |
Series C | 13 |
Series D | 6 |
Seed | 3 |
Others | 3 |
Note: We have considered here, only first round of investments
Arboretum Ventures' Investments by Sector
Arboretum Ventures has a diverse portfolio, with companies operating in the Life Sciences, HealthTech, Enterprise Applications, High Tech and Internet of Things - Industry Applications. Notably, it has invested in 64 Tech companies, 62 Enterprise (B2B) companies, 32 Software companies and at least 27 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 49 |
HealthTech | 21 |
Enterprise Applications | 18 |
High Tech | 16 |
Internet of Things - Industry Applications | 6 |
Others | 20 |
Note: We have considered here, only first round of investments
Arboretum Ventures' Investments by Geography
Arboretum Ventures has made most investments in United States (63), followed by Canada where it has made 1 investment.Country | No. of Investments |
|---|---|
United States | 63 |
Canada | 1 |
Israel | 1 |
Note: We have considered here, only first round of investments
Arboretum Ventures' recent investments
Arboretum Ventures has made 1 investments in 2026 so far - Endogenex.Here are the most recent investments by Arboretum Ventures:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Mar 25, 2026 | United States | Series C | 5907 | - | |
Sep 04, 2025 | United States | Series B | 7621 | ||
May 28, 2025 | United States | Series B | 3876 | [+5] | |
Apr 11, 2025 | United States | Series C | 9891 | ||
Mar 06, 2025 | United States | Series E | 5254 | [+4] |
IPOs and Publicly Listed companies in Arboretum Ventures' Portfolio
3 of Arboretum Ventures' portfolio companies have become public. Shoulder Innovations got listed on the New York Stock Exchange (NYSE), in Jul 2025 at marketcap of $299M and Si-Bone got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $345M.Here are Arboretum Ventures' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jul 31, 2025 | Mar 06, 2025 | Series E | 8781 | |
Oct 17, 2018 | Jun 17, 2016 | Series D | 6331 | |
Feb 14, 2014 | Feb 18, 2007 | Series D | 4835 |
Acquired companies in Arboretum Ventures' Portfolio
22 companies from Arboretum Ventures' portfolio have been acquired. The most recent acquisition was Esperion Therapeutics in May 2026 by ARCHIMED for $*****.Here are Arboretum Ventures' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
May 01, 2026 | Apr 28, 2008 | Series A | 2854 | |
Jun 02, 2025 | Mar 19, 2019 | Series A | 4142 | |
Aug 01, 2023 | Jan 12, 2020 | Series A | 1321 | |
May 03, 2022 | Mar 22, 2018 | Series D | 8033 | |
Oct 28, 2021 | - | - | 5062 |
Team profile of Arboretum Ventures
Arboretum Ventures has a team of 14 members including 3 Partners, 1 Venture Partner and 1 Principal located in United States. Arboretum Ventures' team sits on the board of 1 company.Here is a list of top team members in Arboretum Ventures:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Ann Arbor | |||
Partner | Ann Arbor | - | ||
Partner | - | - | - | |
Venture Partner | - | - | - | |
Principal | Detroit | - |
Co-investors of Arboretum Ventures
Over the past 23 years, 367 investors have co-invested in Arboretum Ventures's portfolio companies. This includes funds and angels.
- Invested before Arboretum Ventures: HHS, Invest Michigan and 116 others have invested in rounds before Arboretum Ventures. There are 5 companies where HHS has invested before Arboretum Ventures and 3 companies where Invest Michigan has invested before Arboretum Ventures.
- Top Co-investors of Arboretum Ventures: 120 investors entered a company along with Arboretum Ventures. These include investors like Versant Ventures (5 companies).
- Invested after Arboretum Ventures: A total of 129 investors have invested in Arboretum Ventures's portfolio after their investments. Top Investors include HHS (4 companies), National Science Foundation (2 companies) and Cadence Healthcare Ventures (2 companies).
Recent News related to Arboretum Ventures
•
Endogenex Raises $50M in Series C Extension FundingFinSMEs•Mar 25, 2026•Endogenex, Arboretum Ventures
•
Boomerang Medical Secures $20M Series B to Advance Neuromodulation Trial for IBDintelligence360•Sep 19, 2025•Hatteras Venture Partners, Arboretum Ventures, boomeranghc.com
•
Boomerang Medical Secures $20 Million in Series B Funding to Advance IBD Neuromodulation TrialBakersfield•Sep 04, 2025•Hatteras Investment Partners, Arboretum Ventures, boomeranghc.com
•
Reprieve Cardiovascular Secures $61M for Heart Failure TrialHIT Consultant•Aug 13, 2025•Reprieve Cardiovascular, Deerfield, Lightstone Ventures, Arboretum Ventures and 5 others
•
Akadeum Life Sciences Secures $20M+ Investment for Cell and Gene Therapy Growthintelligence360•Jun 13, 2025•Akadeum Life Sciences, Michigan Capital Network, Arboretum Ventures, NYBC Ventures
•
Allay Therapeutics Announces $57.5M Series D Financing for Pain PlatformBusiness Wire•Jun 05, 2025•Allay Therapeutics, Bold Ventures, Lightstone Ventures, Clavystbio and 9 others
•
Shoulder Innovations Announces Closing of $40 Million Series E Equity Financingintelligence360•Mar 14, 2025•Shoulder Innovations, Usventure, Sectoral, Arboretum Ventures and 3 others
•
Shoulder Innovations Closes $40M in Series E Equity FinancingFinSMEs•Mar 10, 2025•Shoulder Innovations, USVP, Gilde Healthcare, Gilmartin Capital and 3 others
•
Francis Medical Announces Close of Record $80 Million Series C Equity Financingintelligence360•Jan 20, 2025•Francis Medical, Arboretum Ventures, Solas BioVentures, Orlando Health and 1 other
•
Francis Medical Closes $80M Series C Equity FinancingFinSMEs•Jan 07, 2025•Francis Medical, Arboretum Ventures, Solas BioVentures, Orlando Health and 2 others
